Suphanthaka Sairat. Treatment efficacy of botulinum toxin for orofacial pain and dysfunction : a systematic review and meta-analysis. Master's Degree(General Dentistry). Mahidol University. Mahidol University Library and Knowledge Center. : Mahidol University, 2018.
Treatment efficacy of botulinum toxin for orofacial pain and dysfunction : a systematic review and meta-analysis
Abstract:
This study was a systematic review and meta-analysis to compare the efficacy of BTX and other comparators for treatment of orofacial pain and dysfunction (OFD). Pubmed and Scopus databases were conducted through randomized controlled trial. Eighteen RCTs (946 patients) met the inclusion criteria, and were divided into three groups for pooled outcomes. Group 1 was myofascial pain (7 RCTs, 246) and group 2 was with tension-type headache, chronic daily headache, and migraine (9 RCTs, 598) and group 3 had post-herpetic neuralgia and trigeminal neuralgia (2 RCTs, 102). Intervention was done on the botulinum toxin type A (BTX-A) group, and comparators were ; normal saline (NSS), active drugs and standard treatments. In group 1, BTX-A subjects had a significantly lower VAS score compared to the NSS group (pooled WMD= -1.81, 95% CI: -3.23 to -0.39), BTX-A subjects had a lower VAS score than those in the active treatment group, but this was not significant (pooled WMD = -0.37, 95% CI: -1.89 to 1.16), BTX-A subjects had maximum mouth opening without pain less than the NSS group but this was also not significant (pooled WMD = -1.98, 95% CI: -9.19 to 5.23). In group 2, the BTX-A subjects had a greater VAS score than the NSS subjects but not significant (pooled WMD = 0.22, 95% CI: -0.51 to 0.94). However, the BTXA subjects had significantly lower headache day than the NSS subjects (pooled WMD = -1.66 95% CI: -2.64 to -0.69), and a significantly lower number of drug pill ingest than the NSS subjects (pooled WMD = -2.51 95% CI: -4.42 to -0.60). There were only 2 studies in group 3, so we could not analyze the outcome from this group. In our meta-analysis, BTX-A subjects showed a clinical significant pain relief in myofascial pain group, and the BTX-A subjects had significantly lower headache day and significantly lower number of drug pill ingest than the NSS subjects in the neurovascular group.